Influence of the absolute configuration on pharmacological activity of antihypertensive and antiarrhythmic drugs

Polish Journal of Pharmacology

Volumn 56, Issue 5, 2004, Pages 499-508

  Kulig, Katarzyna ^a   Nowicki, Piotr ^a   Malawska, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Absolute configuration; Antiarrhythmic agents; Antihypertensive drugs; Chirality

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA HYDROXYMETOPROLOL; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CROMAKALIM; CYCLAZOSIN; DILEVALOL; DILTIAZEM; DISOPYRAMIDE; DOXAZOSIN; GALLOPAMIL; LABETALOL; MEPHENDIOXAN; METOPROLOL; NEBIVOLOL; NICARDIPINE; NIFEDIPINE; PINDOLOL; PRAZOSIN; PROPRANOLOL; SOTALOL; SQ 32547; SQ 32926; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANGINA PECTORIS; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR SYSTEM; CHIRALITY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; ENANTIOMER; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; ISOMER; LIVER TOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SIDE EFFECT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TACHYCARDIA;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; HUMANS; ION CHANNEL GATING; STEREOISOMERISM;

EID: 12344336223     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Ball P: What a tonic. Chem Br, 2001, 10, 26-29.
2. 1-adrenoceptor antagonist. Bioorg Med Chem, 2002, 10, 361-369.
3. Blackburn TP, Buckingham RE, Chan WN, Evans JM, Hadley MS, Thompson M, Upton N et al.: Stereochemical differentiation of anticonvulsant and antihypertensive effects in 4-(fluorobenzoylamino)-benzopyrans. Bioorg Med Chem, 1995, 5, 1163-1166.
4. Brenna E, Fuganti C, Serra S: Enantioselective perception of chiral odorants. Tetrahedron: Asymmetry, 2003, 14, 1-42.
5. Burke D, Henderson DJ: Chirality: a blueprint for the future. Br J Anesth, 2002, 88, 563-584
6. Cerqueira PM, Cesario EJ, Bertucci C, Bonato PS, Lanchote VL: Stereoselective metabolism of metoprolol: enantioselectivity of α-hydroxymetoprolol in plasma and urine. Chirality, 2003, 15, 542-549.
7. Chen B, Cai W-M: Influence of CYP2D6*10B genotype on pharmacokinetics of propafenon enantiomers in Chinese subjects. Acta Pharmacol Sin, 2003, 24, 1277-1280.
8. Chen X, Zhong D, Blume H: Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers. Eur J Pharm. Sci, 2000, 10, 11-16.
9. Christiaans JAM, Timmerman H: Cardiovascular hybrid drug: combination of more than one pharmacological property in one single molecule. Eur J Pharm Sci, 1996, 4, 1-22.
10. Crossley R: The relevance of chirality to the study of biological activity. Tetrahedron, 1992, 48, 8155-8178.
11. Gonclaves PVB, Matthes ADCS, Da Cuncha SP, Lanchote VL: Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. Chirality, 2002, 14, 683-687.
12. Gross AS, Eichelbaum M, Mörike K, Mikus G: Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. Br J Clin Pharmacol, 2000, 49, 132-138.
13. Hatano A, Tang R, Walden PD, Lepor H: The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Eur J Pharmacol, 1996, 313, 135-143.
14. Hielbe JP, Bondinell WE, Ruffolo RRJr.: α- and β- Adrenoceptors: from the gene to clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem, 1995, 38, 3415-3444.
15. Inotsume N, Nakano M: Stereoselective determination and pharmacokinetics of dihydropyridines: an updated review. J Biochem Biophys Methods, 2002, 54, 255-274.
16. Japelj I, Budihna MV, Stanovnik L, Kirsch I: Stereoselective and endothelium-independent action of nicardipine on isolated porcine coronary artery. Eur J Pharmacol, 1999, 369, 43-47.
17. Jastrzebska-Wiesek M, Librowski T, Czarnecki R, Marona H, Nowak G: Central activity of xanthone derivatives with chiral center in some pharmacological tests in mice. Pol J Pharmacol, 2003, 55, 461-465.
18. Kappe CO: 4-Aryldihydropyrimidines via the Biginelli condensation: aza-analogs of nifedipine-type calcium channel modulators. Molecules, 1998, 3, 1-9.
19. Kappe CO: Biologically active dihydropyrimidones of the Biginelli-type - a literature survey. Eur J Med Chem, 2000, 35, 1043-1052.
20. Karle CA, Kreye VAW, Thomas D, Röckl K, Kathöfer S, Zhang W, Kiehn J: Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovascular Res, 2001, 49, 361-370.
21. Kennedy IJ, Jane DE: Stereochemistry in drug design. In: Textbook of Drug Design and Discovery. Ed. Krogsgaard-Larsen P, Liljeforst T, Medsen U, Taylor & Francis, London, 2002.
22. Kenny B, Ballard S, Blagg J, Fox D: Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem, 1997, 40, 1293-1315.
23. Kubinyi H: Chemical similarity and biological activities. J Braz Chem Soc, 2002, 13, 717-726.
24. + channel opener. Eur J Pharmacol, 2000, 397, 151-160.
25. Leffingwell JC: Chirality & Bioactivity I. Pharmacology, http//preprint.chemweb.com/medichem/0305001, May 2003.
26. Lukša J, Josič D, Kremser M, Kopitar Z, Milutinovič S: Pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration. J Chromatogr B, 1997, 703, 185-193.
27. MacNiel DJ: The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. Am J Cardiol, 1997, 80, 90G-98G.
28. Maier NM, Franco P, Lindner W: Seperation of enantiomers: needs, challenges, perspectives. J Chromatogr A, 2001, 906, 3-33.
29. Mangralla M, Rossi F, Fici F, Rossi F: Pharmacology of nevibolol. Pharmacol Res, 1998, 38, 419-431.
30. Mehvar R, Brocks DR: Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in human. J Pharm Sci, 2001, 4, 185-200.
31. Mehvar R, Brocks DR, Vakily M: Impact of stereoselectivity on pharmacokinetics and pharmacodynamics of antiarrhythmic drugs. Clin Pharmacokinet, 2002, 41, 8, 533-558.
32. 1-adrenoreceptors: neutral or negative antagonism? Farmaco, 1998, 53, 278-286.
33. 1D-adrenoceptor antagonist. Bioorg Med Chem Lett, 1998, 8, 1353-1358.
34. Mistry B, Leslie JL, Eddington ND: Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. Chirality, 2002, 14, 297-304.
35. Mori Y, Hanada K, Mori T, Tsukahara Y, Hashiguchi M, Ogata H: Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits. Biol Pharm Bull, 2001, 24, 7, 806-810.
36. Mostafavi SA, Foster RT: Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. Int J Pharm, 2000, 202, 97-102.
37. Niva T, Shiraga T, Mitami Y, Terakawa M, Tokuma Y, Kagayama A: Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involement of CYP2D and CYP3A. Drug Metab Dispos, 2000, 28, 1128-1134.
38. Rentsch KM: The importance of stereoselective determination of drugs in the clinical laboratory J Biochem Biophys Methods, 2002, 54, 1-9.
39. Ruffolo RR Jr, Bondinell WE, Hieble JP: α- and β-Adrenoceptors: from the gene to clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem, 1995, 38, 3681-3716.
40. Sato R, Sakamoto K, Yamazaki J, Nagao T: Differences in protective profile of diltiazem isomers in ischemic and reperfused guinea pig hearts. Eur J Pharmacol, 2002, 434, 125-131.
41. Satoh K, Takeda S, Kaneta S, Inagami T, Ichihara K: Effects of nevibolol on ischemia-induced metabolic changes in dog hearts. J Cardiovasc Pharmacol, 2003, 41, 766-770.
42. Sawicki W, Janicki S: Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. Int J Pharm, 2002, 238, 181-189.
43. Singh BN: Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol, 1998, 81, 3D-13D.
44. Stoschitzky K, Klein W, Lindner W: Time to reassess chiral aspects of β-adrenoceptor antagonist. Trends Pharmacol Sci, 1997, 18, 306-307.
45. Stoschitzky K, Koshucharova G, Zweiker R, Maier R, Watzinger N, Fruhwald FM, Klein W: Differing beta-blocker effects of carvedilol and metoprolol. Eur J Heart Fail, 2001, 3, 343-349.
46. Swynghedauw B: Cardiovascular pharmacogenetics and pharmacogenomics. J Clin Basic Cardiol, 2001, 4, 205-210.
47. Thomas RE: Cardiac drugs. In: Burgers's Medicinal Chemistry and Drug Discovery. Ed. Wolff M, Wiley, New York, 1996.
48. Triggle DJ: Stereoselectivity of drug action. Drug Discov Today, 1997, 2, 138-147.
49. Tucker G: Chiral switches. Lancet, 2000, 355, 1085-1087.
50. Wiela-Hojeńska A, Orzechowska-Juzwenko K: Clinical significance of drug stereoselectivity (Polish). Farm Pol, 1995, 51, 653-661.
51. Witkowska M: The role of sympathetic system in the pathomechanism of arterial hypertension - hypotensive drugs inhibiting its activity (Polish). Nadciśnienie tetnicze, 1998, 2, 124-132.
52. Wyrzykowski B: Arterial hypertension: pathophysiology and therapy (Polish). Via Media, Gdańsk, 1998.
53. Zhang X-P, Loke KE, Mital S, Chahwala S, Hintze TH: Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R-(+) enantiomer of amlodipine. J Cardiovasc Pharmacol, 2002, 39, 208-214.
54. Zhou Q, Yao T-W, Yu Y-N, Zeng S: Stereoselective metabolism of propafenone by human CYP3A4 expressed in transgenic Chinese hamster CHL cells lines. Acta Pharmacol Sin, 2001, 22, 944-948.
55. Zhou Q, Yao T-W, Yu Y-N, Zeng S: Concentration-dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2. Pharmazie, 2003, 58, 651-653.
56. Zhou Q, Yao T-W, Zeng S: Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers. World J Gastroenterol, 2001, 7, 830-835.